Anti-inflammatory properties of Lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia

Prostate

Volumn 75, Issue 7, 2015, Pages 706-722

  Bernichtein, Sophie ^a   Pigat, Natascha ^a   Camparo, Philippe ^a   Latil, Alain ^b   Viltard, Mélanie ^c   Friedlander, Gérard ^a   Goffin, Vincent ^a  

^a INSTITUT NECKER ENFANTS MALADES   (France)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^c Institute for European Expertise in Physiology   (France)

Author keywords

BPH; IL 17; IL 6; inflammation; LSESr; mouse model

Indexed keywords

ANDROGEN; CD45 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR7; CYTOKINE; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INTERLEUKIN 17; INTERLEUKIN 6; KI 67 ANTIGEN; MESSENGER RNA; PROLACTIN; PROTEIN BAX; PROTEIN BCL 2; SABAL EXTRACT; MKI67 PROTEIN, MOUSE; PLANT EXTRACT; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE VENTRAL LOBE; PROSTATE WEIGHT; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENE; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; INFLAMMATION; NONPARAMETRIC TEST; ORGAN SIZE; PATHOLOGY; PROSTATIC HYPERPLASIA; SABAL; TRANSGENIC MOUSE;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CYTOKINES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KI-67 ANTIGEN; MALE; MICE; MICE, TRANSGENIC; ORGAN SIZE; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SERENOA; STATISTICS, NONPARAMETRIC;

EID: 84926526097     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22953     Document Type: Article

References (51)

1. Tacklind J, MacDonald R, Rutks I, Wilt TJ,. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2012;(12); CD001423.
2. Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A, Sciarra A, Montorsi F,. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int 2013; 112: 432-441.
3. Kramer G, Mitteregger D, Marberger M,. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 2007; 51: 1202-1216.
4. Drake CG,. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010; 10: 580-593.
5. Robert G, Descazeaud A, Nicolaiew N, Terry S, Sirab N, Vacherot F, Maille P, Allory Y,. De La TA. Inflammation in benign prostatic hyperplasia: A 282 patients' immunohistochemical analysis. Prostate 2009; 69: 1774-1780.
6. De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schroder F, Sciarra A, Tubaro A,. The controversial relationship between benign prostatic hyperplasia and prostate cancer: The role of inflammation. Eur Urol 2011; 60: 106-117.
7. Hmadcha A, Bedoya FJ, Sobrino F, Pintado E,. Methylation-dependent gene silencing induced by interleukin 1beta via nitric oxide production. J Exp Med. 1999; 190: 1595-1604.
8. Kwon OJ, Zhang L, Ittmann MM, Xin L,. Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc Natl Acad Sci U.S.A 2014; 111: E592-E600.
9. Mishra VC, Allen DJ, Nicolaou C, Sharif H, Hudd C, Karim OM, Motiwala HG, Laniado ME,. Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int 2007; 100: 327-331.
10. Kramer G, Marberger M,. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol 2006; 16: 25-29.
11. Wang L, Yang JR, Yang LY, Liu ZT,. Chronic inflammation in benign prostatic hyperplasia: Implications for therapy. Med Hypotheses 2008; 70: 1021-1023.
12. Delongchamps NB, de la RG Chandan, Jones R, Sunheimer R, Threatte G, Jumbelic M, Haas GP,. Evaluation of prostatitis in autopsied prostates-is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol 2008; 179: 1736-1740.
13. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS,. The relationship between prostate inflammation and lower urinary tract symptoms: Examination of baseline data from the REDUCE trial. Eur Urol 2008; 54: 1379-1384.
14. Robert G, Smit F, Hessels D, Jannink S, Karthaus HF, Aalders T, Jansen K, De La TA Mulders, Schalken JA,. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate 2011; 71: 1701-1709.
15. Kramer G, Steiner GE, Handisurya A, Stix U, Haitel A, Knerer B, Gessl A, Lee C, Marberger M,. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002; 52: 43-58.
16. Royuela M, Ricote M, Parsons MS, Garcia-Tunon I, Paniagua R, de Miguel MP,. Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate. J Pathol 2004; 202: 41-49.
17. Giri D, Ittmann M,. Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia. Am J Pathol 2001; 159: 139-147.
18. Mengus C, Le Magnen C, Trella E, Yousef K, Bubendorf L, Provenzano M, Bachmann A, Heberer M, Spagnoli GC, Wyler S,. Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer. J Transl Med 2011; 9: 162.
19. Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C, Marberger MJ,. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003; 56: 171-182.
20. Penna G, Fibbi B, Amuchastegui S, Cossetti C, Aquilano F, Laverny G, Gacci M, Crescioli C, Maggi M, Adorini L,. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol 2009; 182: 4056-4064.
21. Vacherot F, Azzouz M, Gil-Diez-De-Medina S, Colombel M, De La TA Lefrere, Abbou MA, Raynaud CC, Chopin JP,. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia. Prostate 2000; 45: 259-266.
22. Raynaud JP, Cousse H, Martin PM,. Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of Permixon. J Steroid Biochem Mol Biol 2002; 82: 233-239.
23. Carilla E, Briley M, Fauran F, Sultan C, Duvilliers C,. Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. J Steroid Biochem. 1984; 20: 521-523.
24. Paubert-Braquet M, Cousse H, Raynaud JP, Mencia-Huerta JM, Braquet P,. Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol 1998; 33: 340-347.
25. De Monte C, Carradori S, Granese A, Di Pierro GB, Leonardo C, De Nunzio C,. Modern extraction techniques and their impact on the pharmacological profile of Serenoa repens extracts for the treatment of lower urinary tract symptoms. BMC Urol 2014; 14: 63.
26. Vela Navarrete, Garcia R, Cardoso JV, Barat A, Manzarbeitia F, Lopez FA,. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol 2003; 44: 549-555.
27. Paubert-Braquet M, Mencia Huerta, Cousse JM, Braquet H,. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids 1997; 57: 299-304.
28. Silvestri I, Cattarino S, Agliano A, Nicolazzo C, Scarpa S, Salciccia S, Frati L, Gentile V, Sciarra A,. Effect of Serenoa repens (Permixon(R)) on the expression of inflammation-related genes: Analysis in primary cell cultures of human prostate carcinoma. J Inflamm (Lond) 2013; 10: 11.
29. Latil A, Libon C, Templier M, Junquero D, Lantoine-Adam F, Nguyen T,. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int 2012; 110: E301-E307.
30. Parisotto M, Metzger D,. Genetically engineered mouse models of prostate cancer. Mol Oncol 2013; 7: 190-205.
31. Van Coppenolle F, Slomianny C, Carpentier F, Le B X, Ahidouch A, Croix D, Legrand G, Dewailly E, Fournier S, Cousse H, Authie D, Raynaud JP, Beauvillain JC, Dupouy JP, Prevarskaya N,. Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence. Am J Physiol Endocrinol Metab 2001; 280: E120-E129.
32. Van Coppenolle F, Le B X, Carpentier F, Delaby G, Cousse H, Raynaud JP, Dupouy JP, Prevarskaya N,. Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: Comparison with finasteride. Prostate 2000; 43: 49-58.
33. Kindblom J, Dillner K, Sahlin L, Robertson F, Ormandy C, Tornell J, Wennbo H,. Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin. Endocrinology 2003; 144: 2269-2278.
34. Rouet V, Bogorad RL, Kayser C, Kessal K, Genestie C, Bardier A, Grattan DR, Kelder B, Kopchick JJ, Kelly PA, Goffin V,. Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors. Proc Natl Acad Sci U.S.A 2010; 107: 15199-15204.
35. Lai KP, Huang CK, Fang LY, Izumi K, Lo CW, Wood R, Kindblom J, Yeh S, Chang C,. Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia (BPH). Mol Endocrinol 2013; 27: 1617-1631.
36. Barron DA, Rowley DR,. The reactive stroma microenvironment and prostate cancer progression. Endocr Relat Cancer 2012; 19: R187-R204.
37. Park JH, Walls JE, Galvez JJ, Kim MJ, Abate-Shen C, Shen MM, Cardiff RD,. Prostatic Intraepithelial neoplasia in genetically engineered mice. Am J Pathol 2002; 161: 727-735.
38. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, Ward JM, Cardiff RD,. Prostate pathology of genetically engineered mice: Definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004; 64: 2270-2305.
39. Sackmann-Sala L, Chiche A, Mosquera-Garrote N, Boutillon F, Cordier C, Pourmir I, Pascual-Mathey L, Kessal K, Pigat N, Camparo P, Goffin V,. Prolactin-Induced Prostate Tumorigenesis Links Sustained Stat5 Signaling with the Amplification of Basal/Stem Cells and Emergence of Putative Luminal Progenitors. Am J Pathol 2014, 184: 3105-3119.
40. Perry R, Milligan G, Anderson P, Gillon A, White M,. Real-world use of Permixon(R) in benign prostatic hyperplasia-determining appropriate monotherapy and combination treatment. Adv. Ther. 2012; 29: 538-550.
41. Sirab N, Robert G, Fasolo V, Descazeaud A, Vacherot F, Taille AL, Terry S,. Lipidosterolic extract of serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci 2013; 14: 14301-14320.
42. Wennbo H, Kindblom J, Isaksson OG, Tornell J,. Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland. Endocrinology 1997; 138: 4410-4415.
43. Vignozzi L, Cellai I, Santi R, Lombardelli L, Morelli A, Comeglio P, Filippi S, Logiodice F, Carini M, Nesi G, Gacci M, Piccinni MP, Adorini L, Maggi M,. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. J Endocrinol 2012; 214: 31-43.
44. Fibbi B, Penna G, Morelli A, Adorini L, Maggi M,. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2010; 33: 475-488.
45. Ropiquet F, Giri D, Lamb DJ, Ittmann M,. FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation. J Urol 1999; 162: 595-599.
46. Begley LA, Kasina S, MacDonald J, Macoska JA,. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine 2008; 43: 194-199.
47. Iglesias-Gato D, Carsten T, Vesterlund M, Pousette A, Schoop R, Norstedt G,. Androgen-independent effects of Serenoa repens extract (Prostasan(R)) on prostatic epithelial cell proliferation and inflammation. Phytother Res 2012; 26: 259-264.
48. Goffin V, Hoang DT, Bogorad RL, Nevalainen MT,. Prolactin regulation of the prostate gland: a female player in a male game. Nat Rev Urol 2011; 8: 597-607.
49. Tan SH, Dagvadorj A, Shen F, Gu L, Liao Z, Abdulghani J, Zhang Y, Gelmann EP, Zellweger T, Culig Z, Visakorpi T, Bubendorf L, Kirken RA, Karras J, Nevalainen MT,. Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res 2008; 68: 236-248.
50. Bayne CW, Donnelly F, Ross M, Habib FK,. Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Prostate 1999; 40: 232-241.
51. Suzuki M, Oki T, Sugiyama T, Umegaki K, Uchida S, Yamada S,. Muscarinic and alpha 1-adrenergic receptor binding characteristics of saw palmetto extract in rat lower urinary tract. Urology 2007; 69: 1216-1220.